**Table S2**: Toxicity of standard chemotherapy in patients with small cell lung carcinoma and compromised performance status. Of the 105 patients who received standard full dose chemotherapy, toxicity details were available in 86. Thus, the safety set for the cohort of patients who received standard chemotherapy consisted of 86 patients.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **TOXICITY** | **None** | **Grade 1** | **Grade 2** | **Grade 3** | **Grade 4** | **Grade 5** |
| **Mucositis** | 75 (87.2) | 4 (4.7) | 7 (8.1) | 0 | 0 | 0 |
| **Fatigue** | 48 (55.8) | 15 (17.4) | 15 (17.4) | 8 (9.3) | 0 | 0 |
| **Nausea** | 67 (77.9) | 9 (10.5) | 10 (11.6) | 0 | 0 | 0 |
| **Vomiting** | 59 (68.6) | 13 (15.1) | 10 (11.6) | 4 (4.7) | 0 | 0 |
| **Diarrhea** | 61 (70.9) | 9 (10.5) | 8 (9.3) | 7 (8.1) | 1 (1.2) | 0 |
| **Infection** | 55 (64) | 1 (1.2) | 12 (14) | 16 (18.6) | 2 (2.3) | 0 |
| **Hyponatremia** | 27 (31.4) | 24 (27.9) | 3 (3.5) | 28 (32.6) | 4 (4.7) | 0 |
| **Hypokalemia** | 70 (81.4) | 8 (9.3) | 0 | 6 (7) | 2 (2.3) | 0 |
| **Neurotoxicity** | 78 (90.7) | 4 (4.7) | 4 (4.7) | 0 | 0 | 0 |
| **Transaminase elevation** | 68 (79.1) | 12 (14) | 2 (2.3) | 4 (4.7) | 0 | 0 |
| **Hyperbilirubinemia** | 76 (88.4) | 8 (9.3) | 2 (2.3) | 0 | 0 | 0 |
| **Nephrotoxicity** | 82 (95.3) | 4 (4.7) | 0 | 0 | 0 | 0 |
| **Anemia** | 6 (7) | 32 (37.2) | 24 (27.9) | 22 (25.6) | 2 (2.3) | 0 |
| **Neutropenia** | 35 (40.7) | 8 (9.3) | 7 (8.1) | 19 (22.1) | 17 (19.8) | 0 |
| **Febrile neutropenia** | 76 (88.4) | - |  | 5 (5.8) | 3 (3.5) | 2 (2.3) |
| **Thrombocytopenia** | 35 (40.7) | 25 (29.1) | 11 (12.8) | 9 (10.5) | 6 (7) | 0 |